All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mBC - TNBC - L1 - all population, pembrolizumab plus SoC vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05]
0.89 [0.76 ; 1.05 ] KEYNOTE-355 (all population), 2020 1 0% 847 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97]
0.82 [0.69 ; 0.97 ] KEYNOTE-355 (all population), 2020 1 0% 847 NA not evaluable objective responses (ORR)detailed results KEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33]
0.24 [0.17 ; 0.33 ] KEYNOTE-355 (all population), 2020 1 0% 847 NA not evaluable AE (any grade)detailed results KEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87]
1.25 [0.41 ; 3.87 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76]
1.26 [0.91 ; 1.76 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable TRAE (any grade)detailed results KEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70]
1.35 [0.68 ; 2.70 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44]
1.06 [0.78 ; 1.44 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
2.00 [0.09 ; 44.58 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51]
0.83 [0.20 ; 3.51 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71]
1.15 [0.77 ; 1.71 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
2.00 [0.09 ; 44.58 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82]
1.15 [0.47 ; 2.82 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90]
1.00 [0.03 ; 29.90 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
2.00 [0.09 ; 44.58 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48]
1.29 [0.67 ; 2.48 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19]
0.83 [0.58 ; 1.19 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69]
1.13 [0.34 ; 3.69 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36]
0.99 [0.73 ; 1.36 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78]
6.05 [0.34 ; 108.78 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64]
10.16 [0.59 ; 174.64 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-19 23:52 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 60
- treatments: 873
